| Small cell carcinoma of lung

Imdelltra vs Zepzelca

Side-by-side clinical, coverage, and cost comparison for small cell carcinoma of lung.

Deep comparison between: Imdelltra (Amg757) vs Zepzelca with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZepzelca has a higher rate of injection site reactions vs Imdelltra (Amg757) based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zepzelca but not Imdelltra (Amg757), including UnitedHealthcare

Category

Imdelltra (Amg757)

Zepzelca

At A Glance

RouteIV infusion

FrequencyEvery 2 weeks

ClassDLL3-directed bispecific T-cell engager

RouteIV infusion

FrequencyEvery 21 days

ClassAlkylating drug

Indications

Small cell carcinoma of lung

Small cell carcinoma of lung
Small cell lung cancer extensive stage
Small cell lung cancer metastatic

Dosing

Small cell carcinoma of lung Step-up: 1 mg IV infusion on Cycle 1 Day 1, then 10 mg on Days 8 and 15; thereafter 10 mg every 2 weeks as a 1-hour IV infusion until disease progression or unacceptable toxicity.

Small cell lung cancer extensive stage 3.2 mg/m2 IV infusion over 60 minutes every 21 days in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs until disease progression or unacceptable toxicity; reduce to 1.6 mg/m2 every 21 days for moderate or severe hepatic impairment.

Small cell lung cancer metastatic 3.2 mg/m2 IV infusion over 60 minutes every 21 days as a single agent until disease progression or unacceptable toxicity; reduce to 1.6 mg/m2 every 21 days for moderate or severe hepatic impairment.

Contraindications

—

Drug Interactions

26View drug interactions

884View drug interactions

Adverse Reactions

Most common (>=20%) CRS, fatigue, decreased appetite, dysgeusia, pyrexia, constipation, musculoskeletal pain, nausea

Serious CRS, pyrexia, pneumonia, ICANS

Most common (>=30%) Decreased lymphocytes, decreased platelets, decreased hemoglobin, decreased neutrophils, nausea, fatigue

Serious Pneumonia, sepsis, cardio-respiratory arrest, myocardial infarction, febrile neutropenia

Postmarketing Extravasation with tissue necrosis requiring debridement, rhabdomyolysis, tumor lysis syndrome

Pharmacology

Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 on tumor cell surfaces and CD3 on T cells, causing T-cell activation, inflammatory cytokine release, and lysis of DLL3-expressing cells; it may transiently suppress CYP450 enzymes via cytokine release, potentially increasing exposure of CYP substrates for up to 14 days after CRS.

Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts that disrupt DNA binding proteins and repair pathways, leading to cell cycle perturbation and cell death; it also inhibits monocyte activity and reduces macrophage tumor infiltration in vivo.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Imdelltra (Amg757)